Develops drugs for anthrax, smallpox, and opioid overdose emergencies.
Jun 2026Revenue $770M/yrExpenses $836M/yr
No trend
Figures by year
When will Emergent BioSolutions be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $770M and expenses $836M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $743M | $643M | $100M |
| Dec 2024 | $1.04B | $1.15B | −$109M |
| Dec 2023 | $1.05B | $1.78B | −$726M |
| Dec 2022 | $1.12B | $1.29B | −$170M |
| Dec 2021 | $1.77B | $1.43B | $341M |
| Dec 2020 | $1.58B | $1.14B | $439M |
| Dec 2019 | $1.11B | $992M | $114M |
| Dec 2018 | $782M | $693M | $89.8M |
| Dec 2017 | $561M | $437M | $124M |
| Dec 2016 | $489M | $383M | $106M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.